NCT07296250Recruiting
Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT
A Randomized, Prospective Phase II Clinical Trial - Extended Chemotherapy or Not Based on Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Completing Adjuvant Concurrent Chemoradiotherapy
Source: ClinicalTrials.gov · Last updated 22 Dec 2025
Brief summary (registry, in English)
The aim 1 of this trial is the development of the Circulating tumor cells (CTCs) definition of oral cancer minimal residual disease (MRD), and aim 2 is a prospective trial of oral cancer treatment. If this trial is successful, it is expected that it may be able to provide a standard diagnostic tool (MRD in Oral Cavity Squamous Cell Carcinoma (OCSCC)) and treatment mode (extended adjuvant chemotherapy with low-dose oral chemotherapy). The survival rate of patients will be improved.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 21 Nov 2025
- Start date
- 1 Aug 2025
- Primary completion date
- 31 Jul 2026
- Lead sponsor
- Chang Gung Memorial Hospital
- Diseases
- Head and neck cancer, Childhood cancers
- NCT number
- NCT07296250
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 1 Aug 2025 to the primary completion date, 31 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of psychiatric disorders.
Other
- Deemed unsuitable for participation by the attending physician.
- Unwilling to participate in the study.
Who the study is looking for
- Participants with Cancer:
- Aged between 18 and 90 years.
- Histologically confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC).
- Completed surgical treatment and identified as having high-risk factors, followed by concurrent chemoradiotherapy.
- Willing to continue follow-up visits at the hospital after completion of treatment.
Age in the registry: 18 months to 90 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Linkou Chang-Gung Memorial Hospital Coordinator of this site? Confirm its status | Taoyuan City | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.